Please login to the form below
immunotherapies
This page shows the latest immunotherapies news and features for those working in and with pharma, biotech and healthcare.
BMS to test Vedanta’s bacterial therapy with Opdivo
In animal studies presented at this year’s Society for Immunotherapy of Cancer (SITC) meeting, VE800 on its own and alongside PD-1 inhibitors showed anti-tumour effects, including cytotoxic T ... For BMS, the alliance is just one of many seeking to
Latest news
-
CAR-Ts take centre stage as ASH18 comes to a close
of cancer immunotherapy.
-
Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma
The early read-out from the phase 1 programme shows that Amgen’s anti-BCMA drug – one of its bispecific T cell engager (BiTE) immunotherapies – is holding up well in a ... Building on our success with the only approved BiTE immunotherapy available
-
Regeneron’s early stage bispecific shows promise
While Libtayo is far behind the immunotherapy leaders of Merck &Co’s Keytruda and BMS’ Opdivo, the firm is hoping to gain an edge by testing a combination of the two
-
NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer
to reject earlier use of the immunotherapy. ... confidential. Veronique Walsh, general manager, Bristol-Myers Squibb UK &Ireland, said: “Today’s recommendation represents an important step forward in improving outcomes for melanoma patients by
-
NICE lung cancer backing for Keytruda is biggest expansion yet
MSD's immunotherapy Keytruda will be made available to patients with untreated advanced lung cancer in combination with chemotherapy in England, the biggest expansion yet in its use. ... The ruling confirms Keytruda's dominance among PD-1/PD-L1
More from news
Approximately 66 fully matching, plus 347 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
This agreement, which is to combine SQZ’s expertise in cell therapy with Roche’s expertise in immunotherapy will develop cancer products based on the combined technologies, and is anticipated to
-
AstraZeneca: building a new ‘open innovation’ pharma company
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma. ... Open-minded culture. Like the new HQ’s
-
China: AstraZeneca’s new engine for growth and innovation
AZ isn’t a frontrunner overall in lung cancer immunotherapy – MSD consolidated its global lead by gaining a groundbreaking approval of Keytruda in China in July – but AZ has an ace
-
Chinese biotech’s global ambitions
The company has a PD-1 cancer immunotherapy, tislelizumab, in development in China, and believes it can compete in the market alongside multinationals MSD (Merck in the US) and BMS and
-
Biopharma's Future: Made in China
It has just submitted its PD-1 immunotherapy candidate tislelizumab with China’s regulator, and also has a late-stage BTK inhibitor to challenge J&J’s Imbruvica with a potential
More from intelligence
Approximately 1 fully matching, plus 45 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
The company has identified the novel biomarker of tumour mutation burden as a key plank of its growth strategy for the immunotherapy. ... Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as
-
Industry appointments
Zelluna Immunotherapy appoints CSO. Norwegian biotech Zelluna Immunotherapy has named Namir Hassan as its chief scientific officer (CSO). ... antigen. Hassan’s new role, however, will see him manage and plan the next stages of development for the TCR
-
Zelluna Immunotherapy appoints chief technology officer
Arjan Roozen will consolidate the biotech’s manufacturing strategy. Norwegian biotech Zelluna Immunotherapy has bolstered its offering with the appointment of a new chief technology officer.
-
Targovax strengthens board of directors
of our novel and complementary portfolio of cancer immunotherapies.”.
-
Christian Pangratz to head up Sterna Biologicals
Clinical-stage immunotherapy company Sterna Biologicals has appointed its new chief executive officer in the form of Christian Pangratz, who joins the firm from Vectura Group, where he served as senior
More from appointments
Approximately 2 fully matching, plus 42 partially matching documents found.
Latest from PMHub
-
Lucid Group welcomes new magical talent and boosts their medical writing teams with hires in the US and UK
With three years’ healthcare communications experience, and a wealth of knowledge in epilepsy, immunotherapy and oncology Andrew comments, “I have had a very fulfilling first two months at Lucid; the team
-
SWITCHED ONcology Patient Experience Focus Group Full Discussion
The focus group provided deeper insight in to a number of themes including the transformation of cancer understanding, the barriers to cancer diagnosis, the advent of new treatments including immunotherapy, communication
-
Training the next generation of biotech leaders
Technology born out of barcodes, tracking and scanning will become critical as we embrace things like cellular immunotherapies. ... The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to
-
The Big Communication - matching unprecedented clinical advances in immunotherapy with transformative communication
In this white paper, we explore the exciting new frontier of cancer treatment - immuno-oncology (IO) - and what it means for how we communicate with healthcare professionals, patients and carers. For those on the frontline of treating cancer, IO
-
SWITCHED ONcology
We bring together the experts. The patients. The scientists. The technologists. The creatives. We unite powerful insights to make science mean something real. We are stronger together. We are Switched ON. Switched ONcology is the latest thought
More from PMHub
Approximately 11 fully matching, plus 12 partially matching documents found.
Featured jobs
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Account Director
-
Competitive Salary Offered
-
Medical (Scientific) Director
-
£120, 000 benefits
- Account Manager- Healthcare Advertising
-
Negotiable
-
Account Manager
-
Negotiable
- Principal Health Economist - North-West
-
Negotiable
-
Systematic Reviewer - Oxford
-
Negotiable
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
-
Account Manager / Account Director
-
Competative
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
- Business Development Director – Health Education
-
excellent commission
-
Associate Director
-
£75, 000-90, 000
Subscribe to our email news alerts
- Fishawack acquires Blue Latitude Health
- FDA clears Sandoz and Pear’s Opioid Use Disorder app
- As May delays, industry warns again of ‘no-deal’ Brexit
- Clark Health Communications and Egg digital announce new collaboration
- Axovant drops last ‘legacy’ drug to focus on gene therapies
- Healthcare excellence celebrated at 2018 HSJ Awards
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
